MX2020008834A - Biohibrido de neurotoxina botulinica. - Google Patents

Biohibrido de neurotoxina botulinica.

Info

Publication number
MX2020008834A
MX2020008834A MX2020008834A MX2020008834A MX2020008834A MX 2020008834 A MX2020008834 A MX 2020008834A MX 2020008834 A MX2020008834 A MX 2020008834A MX 2020008834 A MX2020008834 A MX 2020008834A MX 2020008834 A MX2020008834 A MX 2020008834A
Authority
MX
Mexico
Prior art keywords
sub
botulinum neurotoxin
receptor
biohybrid
polypeptides
Prior art date
Application number
MX2020008834A
Other languages
English (en)
Inventor
Pål Stenmark
Geoffrey Masuyer
Original Assignee
Toxotech Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toxotech Ab filed Critical Toxotech Ab
Publication of MX2020008834A publication Critical patent/MX2020008834A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/91—Injection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Birds (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a un nuevo dominio de unión a la cadena pesada de la neurotoxina botulínica (BoNT) (HC/TAB) adaptado para unirse sinérgicamente a un receptor de sinaptotagmina (Syt), un receptor de vesícula sináptica 2 asociada (SV2) y un receptor de gangliósido (Gang), así como también polipéptidos que comprenden dicho novedoso HC/TAB, vectores que codifican dichos polipéptidos, y usos de los mismos.
MX2020008834A 2018-02-26 2019-02-21 Biohibrido de neurotoxina botulinica. MX2020008834A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE1850213A SE542539C2 (en) 2018-02-26 2018-02-26 Chimeric botulinum neurotoxin heavy chain binding domain
PCT/EP2019/054310 WO2019162376A1 (en) 2018-02-26 2019-02-21 Botulinum neurotoxin biohybrid

Publications (1)

Publication Number Publication Date
MX2020008834A true MX2020008834A (es) 2021-01-08

Family

ID=65576340

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020008834A MX2020008834A (es) 2018-02-26 2019-02-21 Biohibrido de neurotoxina botulinica.

Country Status (15)

Country Link
US (1) US20200407702A1 (es)
EP (1) EP3759124A1 (es)
JP (2) JP7458999B2 (es)
KR (1) KR20200127175A (es)
CN (1) CN111819189A (es)
AU (1) AU2019223130A1 (es)
BR (1) BR112020017323A2 (es)
CA (1) CA3088928A1 (es)
CL (1) CL2020002186A1 (es)
IL (1) IL276930A (es)
MX (1) MX2020008834A (es)
PH (1) PH12020551270A1 (es)
SE (1) SE542539C2 (es)
SG (1) SG11202006730SA (es)
WO (1) WO2019162376A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019158745A1 (de) * 2018-02-16 2019-08-22 Bontana Therapies Gmbh Nukleinsäure-basiertes botulinum neurotoxin zur therapeutischen anwendung
IL272002A (en) * 2020-01-13 2021-07-29 The Israel Institute Of Biological Res Iibr Methods for identifying active compounds against Clostridium neurotoxin
US20230120677A1 (en) * 2020-01-21 2023-04-20 Trustees Of Dartmouth College Immunologically optimized botulinum toxin light chain variants
CN111675754A (zh) * 2020-05-19 2020-09-18 四川一埃科技有限公司 一种肉毒毒素蛋白晶体结构及晶体制备方法和解析方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102219837B (zh) * 2010-05-20 2013-10-30 中国人民解放军军事医学科学院微生物流行病研究所 重组全长a型肉毒毒素突变体疫苗
JP6336970B2 (ja) * 2012-05-30 2018-06-06 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 操作されたボツリヌス神経毒素
DK3274364T3 (da) * 2015-03-26 2021-10-18 Harvard College Modificeret botulinumneurotoksin
TW201718627A (zh) * 2015-06-11 2017-06-01 梅茲製藥有限兩合公司 重組梭菌神經毒素及其使用與形成方法、包括其之醫藥組合物及對應其之前驅物、編碼前驅物之核酸序列及其獲得方法與前驅物之形成方法、載體與包括核酸序列之重組宿主細胞
GB201607901D0 (en) * 2016-05-05 2016-06-22 Ipsen Biopharm Ltd Chimeric neurotoxins
UA127310C2 (uk) * 2016-05-16 2023-07-19 Презідент Енд Феллоуз Оф Гарвард Колледж Спосіб очищення і активації ботулінічного нейротоксину
CN109476713A (zh) * 2016-06-08 2019-03-15 儿童医学中心公司 工程改造的肉毒杆菌神经毒素

Also Published As

Publication number Publication date
SG11202006730SA (en) 2020-08-28
US20200407702A1 (en) 2020-12-31
JP2021514674A (ja) 2021-06-17
PH12020551270A1 (en) 2021-05-31
CL2020002186A1 (es) 2020-12-28
JP2024069606A (ja) 2024-05-21
CN111819189A (zh) 2020-10-23
SE542539C2 (en) 2020-06-02
BR112020017323A2 (pt) 2020-12-29
RU2020131317A (ru) 2022-03-29
KR20200127175A (ko) 2020-11-10
EP3759124A1 (en) 2021-01-06
CA3088928A1 (en) 2019-08-29
SE1850213A1 (en) 2019-08-27
AU2019223130A1 (en) 2020-09-10
JP7458999B2 (ja) 2024-04-01
WO2019162376A1 (en) 2019-08-29
IL276930A (en) 2020-10-29

Similar Documents

Publication Publication Date Title
MX2020008834A (es) Biohibrido de neurotoxina botulinica.
PH12018501419A1 (en) Pharmaceutical composition comprising bispecific antibody constructs
PH12018502225A1 (en) Anti-il-33 antibodies, compositions, methods and uses thereof
MX2017006530A (es) Nuevos peptidos que se unen al ligando-1 de muerte programada (pd-l1) para formacion de imagen.
WO2013023732A8 (de) Ternesit als anreger für latent-hydraulische und puzzolanische materialien
EP3978532A4 (en) NEW BINDING MOLECULE CLDN18.2
MX2022002111A (es) Novedosos anticuerpos anti-cldn18.2.
MX2018001213A (es) Nuevos metodos para inducir una respuesta inmunitaria.
PH12020550141A1 (en) Antibody molecules to cd138 and uses thereof
MX2021008592A (es) Composiciones de trem y usos de las mismas.
MX2020003093A (es) Anticuerpos anti-cd19 novedosos.
IL291733A (en) Aromatic arylmethylene compounds as Shaker kv1.3 potassium channel blockers
MX2021016098A (es) Moleculas de anticuerpos humanizados contra cd138 y usos de las mismas.
ZA202106602B (en) Claudin 6 antibodies and uses thereof
IL284435A (en) Cyclodextrin dimers, their preparations and uses thereof
EA201991863A1 (ru) Составы амфетамина, препятствующие злоупотреблению
WO2019051327A3 (en) BETA CATENIN FUNCTIONALIZATION AGENTS AND ASSOCIATED METHODS
MX2021014334A (es) Agentes afines a aav9.
MX2021014149A (es) Producto de confiteria.
MX2021000287A (es) Composiciones y métodos relacionados con constructos de dominio de unión a antígeno-fc modificados genéticamente.
WO2020014505A3 (en) COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc-ANTIGEN BINDING DOMAIN CONSTRUCTS
MX2022007960A (es) Nuevos anticuerpos anti-fgfr2b.
MX2022007961A (es) Nuevos anticuerpos anti-fgfr2b.
AR123155A1 (es) Métodos para preparar y purificar detergentes compatibles con el medio ambiente
MX2022007959A (es) Nuevos anticuerpos anti-fgfr2b.